Literature DB >> 31653398

Micro-utrophin Therapy for Duchenne Muscular Dystrophy.

Dongsheng Duan1.   

Abstract

Entities:  

Year:  2019        PMID: 31653398      PMCID: PMC6838911          DOI: 10.1016/j.ymthe.2019.10.011

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  15 in total

1.  Dystrophin immunity in Duchenne's muscular dystrophy.

Authors:  Jerry R Mendell; Katherine Campbell; Louise Rodino-Klapac; Zarife Sahenk; Chris Shilling; Sarah Lewis; Dawn Bowles; Steven Gray; Chengwen Li; Gloria Galloway; Vinod Malik; Brian Coley; K Reed Clark; Juan Li; Xiao Xiao; Jade Samulski; Scott W McPhee; R Jude Samulski; Christopher M Walker
Journal:  N Engl J Med       Date:  2010-10-07       Impact factor: 91.245

2.  Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice.

Authors:  Maria C Vila; James S Novak; Margaret Benny Klimek; Ning Li; Melissa Morales; Alexander G Fritz; Katie Edwards; Jessica F Boehler; Marshall W Hogarth; Travis B Kinder; Aiping Zhang; Davi Mazala; Alyson A Fiorillo; Bonnie Douglas; Yi-Wen Chen; John van den Anker; Qi L Lu; Yetrib Hathout; Eric P Hoffman; Terence A Partridge; Kanneboyina Nagaraju
Journal:  J Pathol       Date:  2019-04-16       Impact factor: 7.996

3.  Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin.

Authors:  Dejia Li; Akshay Bareja; Luke Judge; Yongping Yue; Yi Lai; Rebecca Fairclough; Kay E Davies; Jeffrey S Chamberlain; Dongsheng Duan
Journal:  J Cell Sci       Date:  2010-05-18       Impact factor: 5.285

4.  Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients.

Authors:  Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2018-04-05       Impact factor: 5.695

5.  Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice.

Authors:  S Ebihara; G H Guibinga; R Gilbert; J Nalbantoglu; B Massie; G Karpati; B J Petrof
Journal:  Physiol Genomics       Date:  2000-09-08       Impact factor: 3.107

6.  Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy.

Authors:  Jin-Hong Shin; Xiufang Pan; Chady H Hakim; Hsiao T Yang; Yongping Yue; Keqing Zhang; Ronald L Terjung; Dongsheng Duan
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

7.  Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy.

Authors:  Yi Lai; Gail D Thomas; Yongping Yue; Hsiao T Yang; Dejia Li; Chun Long; Luke Judge; Brian Bostick; Jeffrey S Chamberlain; Ronald L Terjung; Dongsheng Duan
Journal:  J Clin Invest       Date:  2009-02-23       Impact factor: 14.808

8.  Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus.

Authors:  Yongping Yue; Xiufang Pan; Chady H Hakim; Kasun Kodippili; Keqing Zhang; Jin-Hong Shin; Hsiao T Yang; Thomas McDonald; Dongsheng Duan
Journal:  Hum Mol Genet       Date:  2015-08-11       Impact factor: 6.150

9.  Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy.

Authors:  Caroline Le Guiner; Laurent Servais; Marie Montus; Thibaut Larcher; Bodvaël Fraysse; Sophie Moullec; Marine Allais; Virginie François; Maeva Dutilleul; Alberto Malerba; Taeyoung Koo; Jean-Laurent Thibaut; Béatrice Matot; Marie Devaux; Johanne Le Duff; Jack-Yves Deschamps; Inès Barthelemy; Stéphane Blot; Isabelle Testault; Karim Wahbi; Stéphane Ederhy; Samia Martin; Philippe Veron; Christophe Georger; Takis Athanasopoulos; Carole Masurier; Federico Mingozzi; Pierre Carlier; Bernard Gjata; Jean-Yves Hogrel; Oumeya Adjali; Fulvio Mavilio; Thomas Voit; Philippe Moullier; George Dickson
Journal:  Nat Commun       Date:  2017-07-25       Impact factor: 14.919

Review 10.  Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy.

Authors:  Dongsheng Duan
Journal:  Mol Ther       Date:  2018-07-17       Impact factor: 11.454

View more
  3 in total

1.  Catalpol counteracts the pathology in a mouse model of Duchenne muscular dystrophy by inhibiting the TGF-β1/TAK1 signaling pathway.

Authors:  Deng-Qiu Xu; Lei Zhao; Si-Jia Li; Xiao-Fei Huang; Chun-Jie Li; Li-Xin Sun; Xi-Hua Li; Lu-Yong Zhang; Zhen-Zhou Jiang
Journal:  Acta Pharmacol Sin       Date:  2020-09-16       Impact factor: 7.169

Review 2.  Immune Responses to Viral Gene Therapy Vectors.

Authors:  Jamie L Shirley; Ype P de Jong; Cox Terhorst; Roland W Herzog
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

3.  Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies.

Authors:  Patricia Soblechero-Martín; Andrea López-Martínez; Laura de la Puente-Ovejero; Ainara Vallejo-Illarramendi; Virginia Arechavala-Gomeza
Journal:  Neuropathol Appl Neurobiol       Date:  2021-06-04       Impact factor: 8.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.